SGLT2i in CKD:
New Opportunities to Reduce the Progression of Kidney Failure
Brought to you by:
Joslin Diabetes Center in Joint Providership with PlatformQ Health Education, LLC, working in collaboration with the Cardio Renal Society of America (CRSA)
While there are many causes of chronic kidney disease (CKD), including diabetes and hypertension, recent studies of diabetes management with SGLT2 (sodium-glucose cotransporter-2) inhibitors revealed benefits in patients with CKD with or without diabetes. Recognition that SGLT2 inhibitors could have beneficial impacts on renal and cardiovascular protection may provide clinicians with an essential option in their armamentarium for CKD. Therefore, clinicians who care for patients with or at risk for CKD need to be aware of the latest data from completed and ongoing studies of the use of SGLT2i to prevent CKD and slow the progression of kidney disease.
Join an expert clinician panel for 2 educational sessions on the efficacy of SGLT2 inhibitors in renal protection, as well as their initiation and management and coordination of care among various providers with diverse clinical expertise.
In Session 1, “SGLT2 Inhibitors and Chronic Kidney Disease: A Broadening Clinical Perspective,” panelists will provide foundational knowledge and skills to help learners utilize SGLT2i based on evidence-based research. Clinicians will be prepared to initiate SGLT2i earlier in the course of CKD, as well as in people with a wide spectrum of etiologic factors, to more effectively slow the progression of this debilitating condition.
Session 2, “SGLT2 Inhibitors and Their Impact on Chronic Kidney Disease: Case Workshop in Reducing Progression,” will be a peer-to-peer, case-based workshop illustrating the use of this medication class in patients with and without diabetes. Focusing on the prevention of renal disease or disease progression, the workshop will include expert-led presentations of patient cases, interactive polling, and real-time discussions of practice-based decision-making